Relapse according to antipsychotic treatment in schizophrenic patients: A propensity-adjusted analysis

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Millier, Aurelie ^a   Sarlon, Emmanuelle ^b,c,d   Azorin, Jean Michel ^e   Boyer, Laurent ^f   Aballea, Samuel ^a   Auquier, Pascal ^f   Toumi, Mondher ^g  

^a CREATIV CEUTICAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Hospital Center   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; SEDATIVE AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FRANCE; GENERAL PATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROPENSITY SCORE; RECURRENCE RISK; RELAPSE; SCHIZOPHRENIA; TERMINALLY ILL PATIENT; TREATMENT DURATION; ADOLESCENT; CLASSIFICATION; DRUG COMBINATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PROPENSITY SCORE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 79751529218     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-24     Document Type: Article

References (58)

1. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia research 2008, 100(1-3):20-38. 10.1016/j.schres.2007.11.033, 18243663.
2. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009, 35(2):443-457. 10.1093/schbul/sbn018, 2659301, 18417466.
3. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull 2009, 35(2):458-468. 10.1093/schbul/sbn030, 2659302, 18436527.
4. Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, Walpoth M, Fleischhacker WW. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophrenia research 2005, 77(1):25-34. 10.1016/j.schres.2005.01.015, 16005382.
5. Ballerini A, Boccalon RM, Boncompagni G, Casacchia M, Margari F, Minervini L, Righi R, Russo F, Salteri A, Frediani S, et al. Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (psychiatric emergency study and epidemiology) survey. Ann Gen Psychiatry 2007, 6:29. 10.1186/1744-859X-6-29, 2186309, 17983468.
6. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26. 10.1186/1471-244X-5-26, 1156914, 15921508.
7. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and drug safety 2003, 12(1):41-48. 10.1002/pds.783, 12616846.
8. Johnsen E, Svingen GF, Jorgensen HA. Practice regarding antipsychotic therapy: a cross-sectional survey in two Norwegian hospitals. Nord J Psychiatry 2004, 58(4):313-317. 10.1080/08039480410005837, 15370781.
9. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009, 9:24. 10.1186/1471-244X-9-24, 2693495, 19445700.
10. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161(4):692-699. 10.1176/appi.ajp.161.4.692, 15056516.
11. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006, 188:122-127. 10.1192/bjp.188.2.122, 16449697.
12. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. The Journal of clinical psychiatry 2010, 71(2):103-108. 10.4088/JCP.08m04818yel, 19895781.
13. Morgan MG, Scully PJ, Youssef HA, Kinsella A, Owens JM, Waddington JL. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res 2003, 117(2):127-135. 10.1016/S0165-1781(03)00002-7, 12606015.
14. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627. 10.1016/S0140-6736(09)60742-X, 19595447.
15. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. J Clin Psychopharmacol 2008, 28(2):125-131. 10.1097/JCP.0b013e318166f533, 18344721.
16. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17(19):2265-2281.
17. Bebbington PE, Angermeyer M, Azorin JM, Brugha T, Kilian R, Johnson S, Toumi M, Kornfeld A. The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Social psychiatry and psychiatric epidemiology 2005, 40(9):707-717. 10.1007/s00127-005-0955-5, 16151597.
18. Heider D, Angermeyer MC, Winkler I, Schomerus G, Bebbington PE, Brugha T, Azorin JM, Toumi M. A prospective study of Quality of life in schizophrenia in three European countries. Schizophrenia research 2007, 93(1-3):194-202. 10.1016/j.schres.2007.03.005, 17466491.
19. Heider D, Bernert S, Konig HH, Matschinger H, Hogh T, Brugha TS, Bebbington PE, Azorin M, Angermeyer MC, Toumi M. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC). Eur Psychiatry 2009, 24(4):216-224. 10.1016/j.eurpsy.2008.12.013, 19328658.
20. Marwaha S, Johnson S, Bebbington P, Angermeyer MC, Brugha T, Azorin JM, Kilian R, Kornfeld A, Toumi M. Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. The Journal of nervous and mental disease 2008, 196(2):87-94. 10.1097/NMD.0b013e318162aa9c, 18277215.
21. Marwaha S, Johnson S, Bebbington PE, Angermeyer MC, Brugha TS, Azorin JM, Killian R, Hansen K, Toumi M. Predictors of employment status change over 2 years in people with schizophrenia living in Europe. Epidemiologia e psichiatria sociale 2009, 18(4):344-351.
22. Roick C, Heider D, Bebbington PE, Angermeyer MC, Azorin JM, Brugha TS, Kilian R, Johnson S, Toumi M, Kornfeld A. Burden on caregivers of people with schizophrenia: comparison between Germany and Britain. Br J Psychiatry 2007, 190:333-338. 10.1192/bjp.bp.106.025353, 17401040.
23. Schomerus G, Heider D, Angermeyer MC, Bebbington PE, Azorin JM, Brugha T, Toumi M. Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC). Social psychiatry and psychiatric epidemiology 2007, 42(8):617-622. 10.1007/s00127-007-0220-1, 17598057.
24. Schomerus G, Heider D, Angermeyer MC, Bebbington PE, Azorin JM, Brugha T, Toumi M. Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC). Psychological medicine 2008, 38(4):591-597. 10.1017/S0033291707001778, 17935638.
25. Verdoux H. The current state of adult mental health care in France. Eur Arch Psychiatry Clin Neurosci 2007, 257(2):64-70. 10.1007/s00406-006-0693-z, 17131218.
26. APA DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC 1994, 4, APA.
27. CNIL Act n°78-17 of 6 January 1978 on Data Processing, Data Files and Individual Liberties (amended by the Act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data). Journal officiel de la République Française 2004, Assemblée Nationale et Sénat. France, CNIL.
28. WMA Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. 2008, World Medical Association, General Assembly, Seoul, October 2008, WMA.
29. Kay SR, Opler LA, Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 1986, 149:439-448. 10.1192/bjp.149.4.439, 3814927.
30. Lancon C, Reine G, Llorca PM, Auquier P. Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS). Acta Psychiatr Scand 1999, 100(3):237-243. 10.1111/j.1600-0447.1999.tb10851.x, 10493091.
31. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33(6):766-771.
32. Dausch BM, Miklowitz DJ, Richards JA. Global assessment of relational functioning scale (GARF): II. Reliability and validity in a sample of families of bipolar patients. Fam Process 1996, 35(2):175-189. 10.1111/j.1545-5300.1996.00175.x, 8886771.
33. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992, 149(9):1148-1156.
34. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993, (22):39-44.
35. Lancon C, Auquier P, Reine G, Toumi M, Addington D. Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale. Psychiatry Res 1999, 89(2):123-132. 10.1016/S0165-1781(99)00097-9, 10646831.
36. Simpson S, Angus R. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, (212):11-19. 10.1111/j.1600-0447.1970.tb02066.x, 4917967.
37. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676. 10.1192/bjp.154.5.672, 2574607.
38. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. The Journal of nervous and mental disease 1985, 173(6):353-357. 10.1097/00005053-198506000-00005, 3998720.
39. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994, 20(2):297-310.
40. Leplege A, Ecosse E, Verdier A, Perneger TV. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998, 51(11):1013-1023. 10.1016/S0895-4356(98)00093-6, 9817119.
41. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483. 10.1097/00005650-199206000-00002, 1593914.
42. Lader M. What is relapse in schizophrenia?. Int Clin Psychopharmacol 1995, 9(Suppl 5):5-9.
43. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008, 34(2):275-285. 10.1093/schbul/sbm159, 2632403, 18234700.
44. Austin PC, Grootendorst P, Normand SL, Anderson GM. Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Stat Med 2007, 26(4):754-768. 10.1002/sim.2618, 16783757.
45. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophrenia research 2007, 89(1-3):91-100. 10.1016/j.schres.2006.08.017, 2718048, 17070017.
46. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003, 158(3):280-287. 10.1093/aje/kwg115, 12882951.
47. Rajji TK, Ismail Z, Mulsant BH. Age at onset and cognition in schizophrenia: meta-analysis. Br J Psychiatry 2009, 195(4):286-293. 10.1192/bjp.bp.108.060723, 19794194.
48. Centorrino F, Fogarty KV, Sani G, Salvatore P, Cincotta SL, Hennen J, Guzzetta F, Talamo A, Saadeh MG, Baldessarini RJ. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 2005, 20(7):485-492. 10.1002/hup.719, 16116665.
49. Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007, 58(4):489-495. 10.1176/appi.ps.58.4.489, 17412850.
50. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. The Journal of clinical psychiatry 2004, 65(12):1597-1600. 10.4088/JCP.v65n1203, 15641863.
51. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003, 54(1):55-59. 10.1176/appi.ps.54.1.55, 12509667.
52. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67(1):26-36. 10.1001/archgenpsychiatry.2009.175, 20048220.
53. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophrenia research 2007, 90(1-3):186-197. 10.1016/j.schres.2006.09.027, 1937504, 17110087.
54. Citrome L, Jaffe A, Levine J. Monotherapy versus polypharmacy for hospitalized psychiatric patients. Am J Psychiatry 2005, 162(3):631. author reply 632-633, 10.1176/appi.ajp.162.3.631, 15741497.
55. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001, 46(4):334-339.
56. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The Journal of clinical psychiatry 2009, 70(Suppl 4):1-46. quiz 47-48.
57. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127(8 Pt 2):757-763.
58. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003, 160(7):1209-1222. 10.1176/appi.ajp.160.7.1209, 12832232.